Another point that could have represented a strength in this study concerns the absence of early biomarkers of acute kidney injury, such as NGAL or KIM-1, which might have complemented the clinical assessment of AKI severity and contributed to better patient stratification. The gene discussed is LCN2; the disease is acute kidney injury.